poster
Frontage Laboratories has validated a liquid biopsy NGS assay supporting Gradalis Inc.’s Vigil® vaccine. Our cfDNA platform targets 293 oncology genes using automated extraction, high-depth sequencing (~4,000×), and barcode-based bioinformatics to accurately detect low-frequency variants. This enables precise tumor profiling, vaccine monitoring, and supports patient selection for personalized immunotherapy.
Register to gain access to gated resources.
"*" indicates required fields